Phase I, Open-Label, Randomized, Parallel Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of One Intramuscular Injection of Risperidone ISM at Different Dose Strengths in Subjects With Schizophrenia or Schizoaffective Disorder
Phase of Trial: Phase I
Latest Information Update: 16 Oct 2017
At a glance
- Drugs Risperidone (Primary)
- Indications Schizoaffective disorder; Schizophrenia
- Focus Pharmacokinetics; Proof of concept
- Acronyms PRISMA-1
- Sponsors Rovi
- 12 Jul 2016 Results published in the International Clinical Psychopharmacology
- 26 Jun 2015 According to a ROVI media release, results of this study were presented at the 12th European Association for Clinical Pharmacology and Therapeutics (EACPT) Congress, 2015.
- 26 Jun 2015 Results published in the ROVI Media Release.